Last reviewed · How we verify

dafna yahav — Portfolio Competitive Intelligence Brief

dafna yahav pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
The Pfizer mRNA-based BNT162b2 vaccine The Pfizer mRNA-based BNT162b2 vaccine marketed mRNA vaccine SARS-CoV-2 spike protein (S protein) Immunology / Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Arcturus Therapeutics, Inc. · 1 shared drug class
  2. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  3. BioNTech SE · 1 shared drug class
  4. CSPC Megalith Biopharmaceutical Co.,Ltd. · 1 shared drug class
  5. CanSino Biologics Inc. · 1 shared drug class
  6. Clover Biopharmaceuticals AUS Pty · 1 shared drug class
  7. Federal University of Espirito Santo · 1 shared drug class
  8. AIM Vaccine Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for dafna yahav:

Cite this brief

Drug Landscape (2026). dafna yahav — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/dafna-yahav. Accessed 2026-06-10.

Related